Pharmacokinetics biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 1, 1999, Pages 19-28

  Luo, Feng R ^a   Wyrick, Steven D ^a   Chaney, Stephen G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

In vivo biotransformation; Ormaplatin; Oxaliplatin; Pharmacokinetics; Platinum(II)

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; TETRAPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG STRUCTURE; DRUG TRANSFORMATION; ERYTHROCYTE; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; INJECTIONS, INTRAVENOUS; MALE; NERVOUS SYSTEM; ORGANOPLATINUM COMPOUNDS; RATS; RATS, WISTAR;

EID: 0032989376     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050940     Document Type: Article

References (41)

1. Anderson WK, Quagliato DA, Haugwitz RD, Narayanan VL, Wolpert-DeFilippes MK (1986) Synthesis, physical properties, and anti-tumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep 70: 997
2. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, Mckoy WM, Young RC, Ozols RF (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414
3. Boughattas N, Levi F, Fourier C, Lemaigre G, Roulon A, Hecquet B, Mathe G, Reinberg A (1989) Circadian rhythm in toxicities and tissue uptake of 1,2-diaminocyclohexane(trans-l) oxalatoplatinum(II) in mice. Cancer Res 49: 3362
4. Boughattas N, Hecquet B, Fourier C, Bruguerolle B, Trabelsi H, Bouzouita K, Omrane B, Levi F (1994) Comparative pharmacokinetics of oxaliplatin (l-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Dispos 15: 761
5. Carfagna PF, Poma A, Wyrick SD, Holbrook DJ, Chaney SG (1991) Comparisons of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fisher 344 rats at therapeutic and toxic doses. Cancer Chemother Pharmacol 27: 335
6. Chaney SG, Wyrick S, Till GK (1990) In vitro biotransformations of tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (Tetraplatin) in rat plasma. Cancer Res 50: 4539
7. Chaney SG, Gibbons GR, Wyrick SD, Podhasky P (1991) An unexpected biotransformation pathway for tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line. Cancer Res 51: 969
8. Christian MC (1992) The current status of new platinum analogs. Semin Oncol 19: 720
9. Daley-Yates PY (1986) The metabolites of platinum anti-tumor drugs and their biological significance. In: McBrien DCH, Slater TF (eds) Biological mechanisms of platinum antitumor drugs. IRL, Oxford, p 121
10. Daley-Yates PY, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and anti-tumor activity of cisplatin. Biochem Pharmacol 33: 3063
11. Elferink F, Vijgh WJF van der, Poort SEJM van der, Henzen-Logmans SC, Pinedo HM (1984) Influence of hydrolysis products of aqua(1,1-bis(aminoethyl)cyclohexane)sulfatoplatinum(II) on toxicity in rats. Cancer Lett 25: 61
12. Engineer MS, Brown NS, Ho DW, Newman RA, Bulter REA (1989) Comparison of the effects of tetraplatin and cisplatin on renal function and gentamicin pharmacology in rats. Toxicicology 59: 151
13. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Phamarcol 25: 299
14. Fox JL, Lamson ML (1986) Pharmacokinetic data stripping least squares parameter optimization version 2. In: Fox JL (ed) RSTRIP user handbook. Micro Math (Salt Lake City)
15. Kidani Y, Noji M, Tashiro T (1980) Anti-tumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers. Jpn Cancer Res 71: 637
16. 3H]tetrachloro(d,l-trans) 1,2-diaminocyclohexane platinum(IV) (tetraplatin) in mice. Drug Metab Dispos 20: 673
17. Kizu R, Highshi SI, Kidani Y, Miyazaki M (1993) Pharmacokinetics of (1R, 2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31: 475
18. Luo FR, Wyrick SD, Chaney SG (1999) Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44: 29
19. Luo FR, Yen TY, Wyrick SD, Chaney SG (1999) High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin formed in rat plasma in vitro. J Chromatogr B (in press)
20. Luo FR, Wyrick SD, Chaney SG (1999) Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol (in press)
21. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, De Vassale S, Chenu E, Bourut C (1989) Oxalato-platinum or l-OPH, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43: 237
22. Mauldin SK, Gibbons G, Wyrick SD, Chaney SG (1988) Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 48: 5136
23. Misset JL, Kinadi Y, Gastiburu J (1991) Oxalatoplatinum (l-OHP): experimental and clinical studies. In: Howell SB (ed) Platinum and other metal coordination complexes in cancer chemotherapy. Plenum Press, New York, p 369
24. New P, Barohn R, O'Rourke T, Seharaseyan J, Mendell JR, Sahenk Z (1993) Neuropathy following ormaplatin administration: human and laboratory studies. Proc Am Soc Clin Oncol 12: 155
25. O'Rourke TJ, Weiss GR, New P, Burris HA, Rodriguez G, Eckhardt J, Hardy J, Kuhn JG, Fields S, Clark GM, Hoff DD von (1994) Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anticancer Drugs 5: 520
26. Ozols RF (1991) Ovarian cancer: new clinical approaches. Cancer Treat Rev 18: 77
27. Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53: 5970
28. Ferez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC (1991) Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int J Cancer 48: 265
29. Rahman A, Roh JK, Wolpert-DeFilippes MK, Goldin A, Venditti JM, Woolley PV (1988) Therapeutic and pharmacological studies of tetrachloro(d,l-trans)-1,2-diaminocyclohexane-platinum(IV) (tetraplatin), a new platinum analogue. Cancer Res 48: 1745
30. Sakata M, Chaney SG, Spriggs DR (1995) Possible correlation between ormaplatin biotransformations and neurotoxicity. Oncol Res 7: 67
31. Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogstko A, Nash S, McAleer C, Hamilton TC, Roby D, Young RC, Ozols RF, O'Dwyer PJ (1994) Phase-I and pharmacokinetic study of ormaplatin (tetraplain NSC-363812) administered on a day-1 and day-8 schedule. Cancer Res 54: 709
32. Shirazi FH, Molepo JM, Stewart DJ, Ng CE, Raaphost GP, Goel R (1996) Cytotoxicity, accumulation, and efflux of cis-platin and its metabolites in human ovarian carcinoma cells. Toxicol Appl Pharmacol 140: 211
33. Smith JH, Smith MA, Litterst CL, Copley MP, Uozumi J, Boyd MR (1988) Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat. Fundam Appl Toxicol 10: 45
34. Smith MA, Smith JH, Litterst CL, Copley MP, Uozumi J, Boyd MR (1988) In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat. Fundam Appl Toxicol 10: 62
35. Tashio T, Kawada Y, Sakurai Y, Kinadi Y (1989) Anti tumor activity of a new platinum complex, oxalato-(trans-l-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed Pharmacother 43: 251
36. Tutsch KD, Arzoomania RZ, Alberti D, Feierabend C, Robins HL, Spriggs DR (1992) Phase I trial and pharmacokinetic studies of ormaplatin. Proc Am Assoc Cancer Res 33: 536
37. Vijgh WJF van der, Lelieveld P, Klein I, Putten LM van, Pinedo HM (1983) Pharmacokinetics of five platinum compounds in dogs. In: Hacker MP, Douple EB, Krakoff IH (eds) Platinum coordination complexes in cancer chemotherapy. Martinus Nijhoff, Boston, p 140
38. Weiss RB, Christian MC (1993) New cisplatin analogues in development. Drugs 46: 360
39. Wilkoff LJ, Dulmadge EA, Trader MW, Harrison SD Jr, Griswold DP (1987) Evaluation of trans-tetrachloro-1,2-diamimocyclohexaneplatinum(IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 20: 96
40. Wyrick SD, Chaney SG (1987) Tritiated platinum anti-tumor agents containing the trans-d,l-1,2-diaminocyclohexane carrier ligand. J Labelled Compound Radiopharm 25: 349
41. Zou J, Yang XG, Li RC, Lu JF, Wang K (1997) The chirality selectivity in the uptake of platinum (II) complexes with 1,2-cyclohexanediamine isomers as carrier ligand by human erythrocytes. Biometals 10: 37 erythrocytes. Biometals 10: 37